Actualités sur Health

13.06.2006 – 15:37
Mental Health Research Institute and Monash University of Victoria, Australia
Optimized use of Atypical Antipsychotics Associated With Equal Efficacy and Brief Hospital Stays in Patients With Acute Psychosis
Victoria, Australia (ots/PRNewswire) - A new study published by physicians from the Mental Health Research Institute and Monash University of Victoria, Australia, showed that all atypical antipsychotics studied were equally efficacious when used at optimal doses as primary medication for inpatients with acute ...
plus
13.06.2006 – 12:30
Boehringer Ingelheim
More Than 80 Percent of People With Parkinson's Disease Experience Symptoms of Depression, but Nearly Half are not Discussing Them With Their Doctor
Amsterdam (ots) - - New Pan-European Sociological Survey Announced by the European Parkinson's Disease Association (EPDA), Reveals the 'Hidden Face' of PD Over 80 percent of surveyed people with Parkinson's disease (PD) 'often' or 'sometimes' suffer from depressive symptoms as part ...
plus
13.06.2006 – 08:33
Spanish Society of Hypertension
JEWEL Programme Results Show That a New Therapy, Caduet(R), can Optimise Treatment for Patients With Hypertension and Additional Cardiovascular (CV) Risk Factors
Madrid, Spain (ots/PRNewswire) - - Caduet, Single-Pill Amlodipine and Atorvastatin Combination, Helps Patients Reduce Calculated Risk for a Fatal CV Event by 29 to 52 Percent Results from the JEWEL programme show that single-pill amlodipine/atorvastatin therapy, also known as Caduet, is an effective ...
plus
06.06.2006 – 23:24
Quintiles Transnational Corp.
Quintiles Asia Pacific Receives Frost & Sullivan Awards
Research Triangle Park, North Carolina (ots/PRNewswire) - - Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year Quintiles Transnational Corp. today announced that its Quintiles East Asia subsidiary has been named the Asia Pacific region's Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year by the consulting firm Frost ...
plus
06.06.2006 – 12:20
Servier International
Protelos(R) in Treatment of Osteoporosis: Unique Dual Mode of Action Explained and Clinical Benefits on Bone Quality Highlighted
Toronto, Canada (ots/PRNewswire) - - The Increase of OPG Expression Explains the Uncoupling Effect of Protelos(R) on Bone Metabolism Exciting new data presented at the World Congress on Osteoporosis further the understanding of the unique dual mode of action of the anti-osteoporotic agent Protelos(R) ...
plus
06.06.2006 – 09:04
The Leeds Teaching Hospitals
New Phase III Study Shows Strong Efficacy and Favorable Safety Profile With Single-Agent MabCampath(R) (alemtuzumab) for Patients with Previously Untreated B-CLL
Leeds, England (ots/PRNewswire) - - Significant Response Rates and Manageable Side Effects Also Exhibited In Poor-Prognosis and Difficult-to-Treat Patients According to interim data from a new international Phase III study called CAM 307, previously untreated patients with progressive B-cell chronic ...
plus

05.06.2006 – 20:02
Roche Pharmaceuticals
New Study Suggests Combining Breakthrough Therapies Tarceva(R) and Avastin(R) May Provide More Hope for Lung Cancer Patients
Basel, Switzerland (ots/PRNewswire) - A new study(1) suggests that treatment with the combination of the innovative cancer drugs Avastin (bevacizumab) and Tarceva (erlotinib) or Avastin with chemotherapy, improves progression-free survival in patients with recurrent or refractory non-small cell lung cancer ...
plus
05.06.2006 – 08:50
Zeltia Group
Three New Key Studies at ASCO Highlight Antitumoral Activity of Yondelis(R)
Atlanta, Georgia (ots/PRNewswire) - - 86% Rate of Tumour Control in myxoid liposarcomas - Correlation Between DNA Repair Gene Expression and Response Rate in Sarcomas - 78% Rate of Tumour Control in Platinum Pretreated Ovarian Cancer Patients PharmaMar highlights the results of three important studies out of 10 presented on Yondelis(R) at the Annual ...
plus
05.06.2006 – 08:01
AstraZeneca GmbH
Results of Key Phase II Studies Demonstrate Progression Free Survival Advantage for ZD6474 (ZACTIMA) in Lung Cancer
Atlanta (ots/PRNewswire) - - Enrolment to a Pivotal Phase III Study of ZD6474 in Advanced Non-Small Cell Lung Cancer (NSCLC) is Also Underway AstraZeneca today announced at the annual meeting of the American Society of Clinical Oncology (ASCO) further results of two key Phase II studies of the novel ...
plus
03.06.2006 – 14:03
Roche Pharmaceuticals
Largest Ever Data Set Shows Consistent Benefits With Avastin When Used in Combination With Different Chemotherapy Treatments
Basel, Switzerland (ots/PRNewswire) - - Real World Practice Confirms Avastin's Efficacy and Safety in Advanced Colorectal Cancer New data from 4,000 patients show that Avastin (bevacizumab rhuMAb-VEGF) enables patients with advanced colorectal cancer (CRC) to live longer without progression of their ...
plus
01.06.2006 – 13:00
MEDISTICK GmbH
MEDISTICK® - carry your family physician in your pocket
Mittelhäusern (ots) - MEDISTICK GmbH, a young Swiss company, has developed what they believe is the world's first personal multilingual medical record device. The innovative technical software solution on an UBS memory stick format helps to provide swift accurate medical diagnoses and treatments to everybody independent of their whereabouts or language skills. The encrypted software© program loaded on the memory ...
plus
26.05.2006 – 13:05
GLCC, London
The Tempus International Awards for Lung Cancer Journalism
London (ots/PRNewswire) - - The Global Lung Cancer Coalition (GLCC) is Excited to Launch the Tempus Journalism Awards, a Global Initiative to Recognise Excellence in Lung Cancer Reporting Lung cancer is the leading cause of cancer-related death in both men and women and every year more than 1.2 million new cases of lung and bronchial cancer are diagnosed worldwide. Sufferers of lung cancer are often stigmatised ...
plus

25.05.2006 – 14:09
Isotechnika Inc.
Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin ...
plus
23.05.2006 – 21:04
AstraZeneca GmbH
Treating Both Poles of Bipolar Disorder: Pivotal Study Confirms Potential of Quetiapine as First Atypical Antipsychotic Monotherapy
Toronto (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US and non-UK) The results of a pivotal study confirm the potential of quetiapine fumarate (SEROQUEL) as a monotherapy (treatment with a single antipsychotic medicine) for acute bipolar depression. Quetiapine is an atypical ...
plus
23.05.2006 – 17:06
Boehringer Ingelheim
New Data Shed Light on the Global Incidence of Constipation
Ingelheim, Germany (ots/PRNewswire) - - Not for Distribution or Publication in the United States New omnibus data from the largest global survey due to be published, conducted on the epidemiology of constipation, were presented today at the Digestive Disease Week congress in Los Angeles. The survey, sponsored by Boehringer Ingelheim, offers new insights into the incidence of constipation and shows that ...
plus
22.05.2006 – 06:05
Boehringer Ingelheim
New Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25% of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international gastroenterology congress Digestive Disease Week (DDW) 2006 ...
plus
21.05.2006 – 09:06
AstraZeneca GmbH
Two Thirds of Family Doctors Believe COPD will be the Leading Cause of Death in 2020
San Diego, California (ots/PRNewswire) - - For Accredited International Healthcare Journalists Only - Management of Exacerbations `Crucial' to Reduce COPD Mortality Survey results from the `Time to Live' report, presented today at the American Thoracic Society International Congress, show over two thirds of primary care physicians (66%) fear COPD will be ...
plus
18.05.2006 – 15:35
European Hematlogy Association
Invitation to the International Press Conference of the 11th Congress of the European Hematology Association
Rotterdam, Netherlands (ots/PRNewswire) - - RAI CONVENTION CENTRE, AMSTERDAM Presentation of results of groundbreaking hematological research in the fields of donor stem-cell transplantation and thrombosis The 11th Congress of the European Hematology Association (EHA) is being held from June 15 to 18 ...
plus

17.05.2006 – 12:06
Boston Scientific
Boston Scientific to Add New European Institute for Therapy Advancement Campus to Global Medical Education Network
Natick, Massachusetts and Paris (ots/PRNewswire) - - New Second-Generation Training Center in Brussels to Help Medical Professionals Advance Standard of Patient Care Boston Scientific Corporation (NYSE: BSX) today announced plans for the construction of a new state-of-the art medical training facility in ...
plus
11.05.2006 – 16:07
ETHICON, INC.
ETHICON Announces CE Mark Approval of New Device to Treat Female Stress Incontinence
Somerville, New Jersey (ots/PRNewswire) - ETHICON Women's Health & Urology announced today that it received CE Mark approval in Europe to market the GYNECARE TVT SECUR(i) System for female stress urinary incontinence (SUI). This new mid-urethral sling device maintains many of the key elements that made GYNECARE TVT the gold standard in SUI surgery, and optimizes ...
plus
09.05.2006 – 16:06
Boston Scientific
Boston Scientific to Release Latest Clinical Trial Results on Market-Leading TAXUS(R) Coronary Stent Systems at EuroPCR
Natick, Massachusetts (ots/PRNewswire) - - Results to Include Nine-Month Data on TAXUS(R) Liberte(TM) Stent Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Paris Course on Revascularization (EuroPCR), which runs from May ...
plus
09.05.2006 – 08:04
Gemplus
Gemplus Wins Contract for 3.7 Million Secure Healthcare Cards in Mexico
Luxembourg and Mexico City (ots/PRNewswire) - - Gemplus Delivers Healthcare ID Card, Software and Services to Mexico's Seguro Popular for Patient Data Storage Gemplus International S.A. (Euronext: LU0121706294 - GEM and NASDAQ: GEMP), a world leading provider of secure card solutions announces the delivery of 3.7 million smart healthcare cards to Seguro ...
plus
04.05.2006 – 10:04
Fendi Presse
Fendi and Sharon Stone to Benefit amfAR
Paris (ots/PRNewswire) - Fendi and Sharon Stone have joined forces for the amfAR - American Foundation for AIDS Research. (Photo: http://www.newscom.com/cgi-bin/prnh/20060504/211357-a ) (Photo: http://www.newscom.com/cgi-bin/prnh/20060504/211357-b ) Sharon Stone, in collaboration with Fendi, has created a luxury travel set that she will auction off, with all profits to be presented to amfAR at the 'Cinema ...
plus
28.04.2006 – 12:20
Bristol-Myers Squibb SA
96-Week Data Show Entecavir Demonstrates More Viral Suppression Compared to Lamivudine in Hepatitis B Infected E-Antigen Negative Patients
Vienna, Austria (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more viral load suppression compared to lamivudine in nucleoside-naive, chronic hepatitis B e-antigen-negative (HBeAg-) patients. Data ...
plus

28.04.2006 – 07:35
Roche Pharmaceuticals
Herceptin Receives Positive Opinion in Europe for Early Use in HER2-Positive Breast Cancer
Basel, Switzerland (ots/PRNewswire) - - Important Step Towards Broad Access of Herceptin for Women With Aggressive Form of Breast Cancer Roche today announced that the European Union's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin following surgery and standard chemotherapy as adjuvant treatment ...
plus
27.04.2006 – 09:24
Zeltia Group
Zeltia Increases R&D Investment by 32.2% in the First Quarter 2006
Madrid (ots/PRNewswire) - - Revenue Amounted to 14.8 Million Euros - Marketing Expenditure Increased 52.1% to 5.1 Million Euros - The Group Invested 11.8 Million Euros in Research and Development, Up 32% Zeltia S.A. (ZEL SM; ZEL MC) today presented its financial results for the first quarter of 2006, which showed a significant increase in Research & Development (R&D) spend, to 11.8 million euros. ...
plus
25.04.2006 – 15:21
Isotechnika Inc.
Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ...
plus
24.04.2006 – 09:47
NeuroPharma
Neuropharma Introduces in Clinical Trials its First Medicine for the Treatment of Alzheimer's
Madrid, Spain (ots/PRNewswire) - - Preliminary Tests Demonstrate That the NP031112 Molecule has a Very Innovative Therapeutic Potential - Phase I Will Consist of Two Stages: in the First One the Drug Will be Administrated in Scalating Single Doses, and in the Second One, in a Repeated Dose for Seven Days. Neuropharma, a subsidiary of the Zeltia Group ...
plus
21.04.2006 – 19:15
Boston Scientific
Boston Scientific Completes Combination With Guidant
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today announced that it has completed its combination with Guidant Corporation (NYSE: GDT), creating a global leader in cardiovascular devices and one of the largest medical technology companies in the world. In a related transaction before the closing of the Boston Scientific-Guidant transaction, Guidant and Abbott closed ...
plus
13.04.2006 – 12:04
World Federation of Hemophilia
Global Hemophilia Community Campaigns to Stop Childhood Deaths
Montreal, Canada (ots/PRNewswire) - "No child born with a bleeding disorder should have to live with pain, disability, or the prospect of early death," says Mark Skinner, president of the World Federation of Hemophilia (WFH). He was speaking on the eve of World Hemophilia Day, (April 17) which has adopted the message this year of Treatment for all! "With treatment, a person with hemophilia can expect to live ...
plus

Précédent78798081828384858687Suivant